Inhibition of p38 mitogen-activated protein kinase-induced apoptosis in cultured mature oligodendrocytes using SB202190 and SB203580

Neurochemistry International

Volumn 51, Issue 1, 2007, Pages 16-24

  Hamanoue, Makoto ^a   Sato, Kenichiro ^a   Takamatsu, Ken ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Caspase; Mouse; Oligodendroglia; P38 mitogen activated protein kinases; Survival

Indexed keywords

2',3' CYCLIC NUCLEOTIDE 3' PHOSPHODIESTERASE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CASPASE 3; CASPASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; NICK END LABELING; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT;

ADENOSINE TRIPHOSPHATE; ANIMALS; APOPTOSIS; CASPASES; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; ENZYME INHIBITORS; IMIDAZOLES; OLIGODENDROGLIA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORIC MONOESTER HYDROLASES; PYRIDINES; RATS; RATS, WISTAR; STEM CELLS;

RATTUS;

EID: 34347267559     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2007.03.005     Document Type: Article

References (23)

1. Baron W., Metz B., Bansal R., Hoekstra D., and de Vries H. PDGF and FGF-2 signaling in oligodendrocyte progenitor cells: regulation of proliferation and differentiation by multiple intracellular signaling pathways. Mol. Cell Neurosci. 15 (2000) 314-329
2. Bhat N.R., Zhang P., and Bhat A.N. Cytokine induction of inducible nitric oxide synthase in an oligodendrocyte cell line: role of p38 mitogen-activated protein kinase activation. J. Neurochem. 72 (1999) 472-478
3. Borsch-Haubold A.G., Pasquet S., and Watson S.P. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase. J. Biol. Chem. 273 (1998) 28766-28772
4. Campos C.B., Bedard P.A., and Linden R. Requirement of p38 stress-activated MAP kinase for cell death in the developing retina depends on the stage of cell differentiation. Neurochem. Int. 49 (2006) 494-499
5. Canoll P.D., Musacchio J.M., Hardy R., Reynolds R., Marchionni M.A., and Salzer J.L. GGF/neuregulin is a neuronal signal that promotes the proliferation and survival and inhibits the differentiation of oligodendrocyte progenitors. Neuron 17 (1996) 229-243
6. Crouch S.P., Kozlowski R., Slater K.J., and Fletcher J. The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J. Immunol. Methods 160 (1993) 81-88
7. Cuenda A., Rouse J., Doza Y.N., Meier R., Cohen P., Gallagher T.F., Young P.R., and Lee J.C. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364 (1995) 229-233
8. Davies S.P., Reddy H., Caivano M., and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351 (2000) 95-105
9. Denizot F., and Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods 89 (1986) 271-277
10. Fragoso G., Martinez-Bermudez A.K., Liu H.N., Khorchid A., Chemtob S., Mushynski W.E., and Almazan G. Developmental differences in HO-induced oligodendrocyte cell death: role of glutathione, mitogen-activated protein kinases and caspase 3. J. Neurochem. 90 (2004) 392-404
11. Hall-Jackson C.A., Goedert M., Hedge P., and Cohen P. Effect of SB 203580 on the activity of c-Raf in vitro and in vivo. Oncogene 18 (1999) 2047-2054
12. Hamanoue M., Yoshioka A., Ohashi T., Eto Y., and Takamatsu K. NF-kappaB prevents TNF-alpha-induced apoptosis in an oligodendrocyte cell line. Neurochem. Res. 29 (2004) 1571-1576
13. Han J., Lee J.D., Bibbs L., and Ulevitch R.J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265 (1994) 808-811
14. Hida H., Nagano S., Takeda M., and Soliven B. Regulation of mitogen-activated protein kinases by sphingolipid products in oligodendrocytes. J. Neurosci. 19 (1999) 7458-7467
15. Hisahara S., Takano R., Shoji S., Okano H., and Miura M. Role of caspase-1 subfamily in cytotoxic cytokine-induced oligodendrocyte cell death. J. Neural. Transm. Suppl. (2000) 135-142
16. Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy-from molecular mechanisms to therapeutic benefits. Biochim. Biophys. Acta 1754 (2005) 253-262
17. Lee J.C., Laydon J.T., McDonnell P.C., Gallagher T.F., Kumar S., Green D., McNulty D., Blumenthal M.J., Heys J.R., Landvatter S.W., et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372 (1994) 739-746
18. Louis J.C., Magal E., Muir D., Manthorpe M., and Varon S. CG-4, a new bipotential glial cell line from rat brain, is capable of differentiating in vitro into either mature oligodendrocytes or type-2 astrocytes. J. Neurosci. Res. 31 (1992) 193-204
19. Maruyama M., Sudo T., Kasuya Y., Shiga T., Hu B., and Osada H. Immunolocalization of p38 MAP kinase in mouse brain. Brain Res. 887 (2000) 350-358
20. Stariha R.L., and Kim S.U. Mitogen-activated protein kinase signalling in oligodendrocytes: a comparison of primary cultures and CG-4. Int. J. Dev. Neurosci. 19 (2001) 427-437
21. Takeda K., and Ichijo H. Neuronal p38 MAPK signalling: an emerging regulator of cell fate and function in the nervous system. Genes Cells 7 (2002) 1099-1111
22. Tomaselli B., Podhraski V., Heftberger V., Bock G., and Baier-Bitterlich G. Purine nucleoside-mediated protection of chemical hypoxia-induced neuronal injuries involves p42/44 MAPK activation. Neurochem. Int. 46 (2005) 513-521
23. Wadsworth S.A., Cavender D.E., Beers S.A., Lalan P., Schafer P.H., Malloy E.A., Wu W., Fahmy B., Olini G.C., Davis J.E., Pellegrino-Gensey J.L., Wachter M.P., and Siekierka J.J. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J. Pharmacol. Exp. Ther. 291 (1999) 680-687